Delcath Systems (NASDAQ:DCTH) Posts Earnings Results, Beats Expectations By $0.07 EPS

Delcath Systems (NASDAQ:DCTH) issued its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07, FiscalAI reports. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%.The firm had revenue of $24.99 million during the quarter, compared to analysts’ expectations of $23.51 million.

Here are the key takeaways from Delcath Systems’ conference call:

• Q1 operational momentum: the company activated 4 centers, reported record new patient starts, has 29 REMS?certified sites and is modifying its activation goal to 37 centers by year?end (40 by Q1 2027), reflecting broad commercial interest.
• Strong topline and guidance: Q1 revenue rose to $25.0M (vs $19.8M LY), ending cash of $89.3M, and management reiterated at least $100M revenue for 2026 with expected positive adjusted EBITDA for the remainder of the year.
• Clinical programs progressing but paced slowly: the metastatic CRC trial has 13 active screening sites with 7 patients enrolled (target 26 sites by year?end; interim readout late 2027) and the metastatic breast program has 4 sites active with a target of 15 by late 2026, so readouts remain long?dated and enrollment is ramping.
• CHOPIN data driving adoption: publication of the CHOPIN results in The Lancet Oncology (combination HEPZATO + immunotherapy showing ~76% response and survival separation) is cited as a key factor changing prescribing patterns and motivating many new sites to adopt a CHOPIN?like protocol.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH traded up $0.24 during midday trading on Friday, hitting $11.48. The company had a trading volume of 569,665 shares, compared to its average volume of 339,366. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $18.23. The stock has a market cap of $395.60 million, a price-to-earnings ratio of 1,148.00 and a beta of 0.54. The business’s 50-day simple moving average is $9.86 and its 200-day simple moving average is $9.82.

Institutional Investors Weigh In On Delcath Systems

Hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System acquired a new stake in Delcath Systems during the second quarter worth $26,000. Russell Investments Group Ltd. acquired a new stake in shares of Delcath Systems in the third quarter valued at $29,000. Tower Research Capital LLC TRC acquired a new stake in shares of Delcath Systems in the second quarter valued at $40,000. Legal & General Group Plc purchased a new position in Delcath Systems in the second quarter valued at $46,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Delcath Systems in the second quarter valued at $151,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on DCTH shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Delcath Systems in a research report on Friday, January 9th. Evercore set a $27.00 target price on Delcath Systems in a report on Thursday, February 26th. BTIG Research dropped their target price on Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Finally, Wall Street Zen downgraded Delcath Systems from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Delcath Systems currently has an average rating of “Moderate Buy” and an average target price of $22.50.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.